Heparin Label Update Aims to Clarify Dosage Strength

Federal drug regulators have ordered a warning label update for the blood thinner heparin, which is designed to better explain the drug’s dosage strengths. 

The FDA issued a drug safety communication on December 6, indicating that label changes will affect Heparain Lock Flush Solution, USP and Heparin Sodium Injection, USP.

The medications will be required to clearly stat the strength of the entire container, in addition to how much of the drug’s active ingredient is in a 1 milliliter (mL) dose.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

The dosage strength on the old labels simply read: 5,000 USP units per mL. But the updated labels will read: 50,000 USP units per 10 mL (5,000 USP units per mL).

The FDA says the new labels will “eliminate the need for health care professionals to calculate the total amount of heparin medication in a product containing more than 1 mL, thereby reducing the risk of miscalculations that may result in medication errors.”

Concerns began surfacing about risks associated with heparin dosage labels in 2009. Manufacturers are required to have the new labels in place by May 1, 2013.

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Third Track of Camp Lejeune Illnesses and Diseases To Be Selected For Case Specific Workup
Third Track of Camp Lejeune Illnesses and Diseases To Be Selected For Case Specific Workup (Posted today)

The U.S. government has proposed claims of esophageal cancer, miscarriage, dental side effects, and hypersensitivity skin disorder be used for a third batch of potential Camp Lejeune bellwether lawsuits.